Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | New applications for MRD measurement in myeloma: MRD ‘over time’

Ola Landgren, MD, PhD, from Memorial Sloan Kettering Cancer Center, NY, describes novel uses for minimal residual disease (MRD) measurement in multiple myeloma (MM), including his experience of monitoring MRD ‘over time’, how we might think of the definition of relapse going forward, and the studies his institute is working on in these areas. This video was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.